Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864259 | 0.77 | PIK3CD (0.41) | PIK3CDADRA1DHTR2CHTR7ADRA1A | |
| SCHEMBL15184790 | 0.77 | PIK3CD (0.41) | PIK3CDADRA1DHTR2CHTR7ADRA1A | |
| SCHEMBL717152 | 0.74 | PIK3CD (0.40) | PIK3CDOPRK1ADRA1DHTR2CHTR7 | |
| SCHEMBL863597 | 0.73 | — | — | |
| SCHEMBL718044 | 0.71 | GPR6 (0.38) | PIK3CDOPRK1SOS1 | |
| SCHEMBL722778 | 0.69 | OPRK1 (0.42) | OPRK1SOS1 | |
| SCHEMBL15184765 | 0.68 | HTR7 (0.43) | PIK3CDADRA1DHTR2CHTR7ADRA1A | |
| SCHEMBL863562 | 0.68 | HTR7 (0.43) | PIK3CDADRA1DHTR2CHTR7ADRA1A | |
| SCHEMBL864109 | 0.67 | HTR7 (0.42) | PIK3CDADRA1DHTR2CHTR7ADRA1A | |
| SCHEMBL15184816 | 0.67 | HTR7 (0.42) | PIK3CDADRA1DHTR2CHTR7ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885OPRK1 600/4885IDH1 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.